跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 18 天前精选AI 评分85

FDA 批准 Dr. Reddy’s Laboratories 制造的 lenacapavir 仿制药

STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries

AI 导读

FDA 批准了 Dr. Reddy’s Laboratories 制造的 lenacapavir 仿制药,该药每年每人费用为 40 美元,有助于在低收入国家扩大 HIV 预防药物的可及性。

推荐理由

FDA 批准了 Dr. Reddy’s Laboratories 制造的 lenacapavir 仿制药,有助于降低 HIV 预防药物的成本。

正文

By Ed Silverman

Nov. 2, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

After months of anticipation, the Food and Drug Administration gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicine, a key step in widening access for dozens of low- and middle-income countries.

The company, one of the world’s largest generic drugmakers, plans to start shipping the medicine next month as part of an effort propelled, in part, by several global health organizations to ensure the drug becomes available in lower-income countries as quickly as possible. The annual cost per person will be $40, comparable to daily tablets.

Known as lenacapavir, the injectable drug is widely seen as a game-changing tool for eradicating HIV because it offers virtually complete protection against contracting the virus with just one administration every six months. The brand-name version, which is known as Yetzugo in the U.S., is marketed by Gilead Sciences and was approved by the FDA last year.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com